Multihance Versus Magnevist in Breast MRI

Summary

To show if one MRI contrast agent is better than another one in the diagnosis of malignant breast lesions compared to histopathology

Timeline

Start

2007-07

Primary completion

2009-12

Completion

2009-12

Outcome

Met primary endpoint

paper Significant superiority for gadobenate dimeglumine was noted by readers 1, 2, and 3 for malignant lesion detection rate PMID 21163915 ↗

paper Gadobenate dimeglumine is superior to gadopentetate dimeglumine for breast cancer diagnosis. PMID 21163915 ↗

Publications

• Martincich L, Faivre-Pierret M, Zechmann CM, Corcione S, van den Bosch HC, Peng WJ, Petrillo A, Siegmann KC, Heverhagen JT, Panizza P, Gehl HB, Diekmann F, Pediconi F, Ma L, Gilbert FJ, Sardanelli F, Belli P, Salvatore M, Kreitner KF, Weiss CM, Zuiani C. Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for Breast MR imaging (DETECT Trial). Radiology. 2011 Feb;258(2):396-408. doi: 10.1148/radiol.10100968. Epub 2010 Dec 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gadobenate dimeglumine	Diagnostic / imaging agent	0.5 unknown	—
Subject	Gadopentetate dimeglumine	Diagnostic / imaging agent	0.5 unknown	—

Indications